AHS Hospital Corp.

Consolidated Financial Statements and Supplemental Information
December 31, 2025 and 2024

AHS Hospital Corp.
Index
December 31, 2025 and 2024

pwc

Report of Independent Auditors

To the Board of Trustees of Atlantic Health System, Inc.

Opinion

We have audited the accompanying consolidated financial statements of AHS Hospital Corp. and its subsidiaries (the "Company"), which comprise the consolidated balance sheets as of December 31, 2025 and 2024, and the related consolidated statements of operations, of changes in net assets and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The accompanying consolidating statements of operations for the years ended December 31, 2025 and 2024 (the “supplemental information”) is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. The consolidating information is not intended to present, and we do not express an opinion on, the financial position, results of operations, changes in net assets and cash flows of the individual divisions of the Company. The supplemental information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The supplemental information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

PricewaterhouseCoopers LLP

New York, New York
April 14, 2026

AHS Hospital Corp.
Consolidated Balance Sheets
December 31, 2025 and 2024

(in thousands)	2025	2024
Assets		
Current assets		
Cash and cash equivalents	$ 394,370	$ 244,580
Assets limited as to use	61,443	67,872
Patient accounts receivable, net	469,763	465,950
Other current assets	286,746	278,957
Total current assets	1,212,322	1,057,359
Assets limited as to use, net of current portion	3,079,525	2,804,958
Long-term investments and other assets	650,356	601,626
Property, plant and equipment, net	1,552,311	1,534,904
Right of use assets, net	327,586	347,760
Total assets	$ 6,822,100	$ 6,346,607
Liabilities and Net Assets		
Current liabilities		
Current portion of long-term debt	$ 13,485	$ 19,136
Current portion of lease liability	51,294	49,576
Accounts payable and accrued expenses	601,300	565,117
Estimated amounts due to third party payers	63,020	57,841
Total current liabilities	729,099	691,670
Accrued employee benefits and other	278,149	291,637
Long-term debt, net of unamortized bond premium, debt issuance costs, and current portion	1,353,412	1,366,897
Long-term lease liability, net of current portion	287,461	308,001
Total liabilities	2,648,121	2,658,205
Net assets		
Without donor restrictions controlled by the Hospital	3,939,389	3,460,230
Without donor restrictions attributable to noncontrolling interests	4,061	4,244
Without donor restrictions	3,943,450	3,464,474
With donor restrictions	230,529	223,928
Total net assets	4,173,979	3,688,402
Total liabilities and net assets	$ 6,822,100	$ 6,346,607

The accompanying notes are an integral part of these consolidated financial statements.

AHS Hospital Corp.
Consolidated Statements of Operations
Years Ended December 31, 2025 and 2024

(in thousands)	2025	2024
Revenues, gains and other support		
Net patient service revenue	$ 4,752,678	$ 4,308,381
Other revenue	82,673	48,623
Net assets released from restrictions	16,713	15,827
Total revenues, gains and other support	4,852,064	4,372,831
Expenses		
Salaries	2,175,581	2,021,210
Supplies and other expenses	1,831,283	1,598,603
Employee benefits	465,879	410,607
Depreciation	193,484	183,188
Interest	50,062	55,792
Total operating expenses	4,716,289	4,269,400
Operating income	135,775	103,431
Change in net unrealized gains	103,341	69,325
Investment income, net	223,722	150,402
Nonoperating loss, net	(5,977)	(5,697)
Excess of revenues over expenses	456,861	317,461
Other changes in net assets without donor restrictions		
Noncontrolling interest	(183)	-
Equity transfers to related parties	(44,606)	(157,918)
Change in funded status of benefit plans	26,294	16,018
Net assets released from restrictions for capital purposes	26,818	21,006
Government grants used for capital purchases	13,792	54,958
Increase in net assets without donor restrictions	$ 478,976	$ 251,525

The accompanying notes are an integral part of these consolidated financial statements.

AHS Hospital Corp.
Consolidated Statements of Changes in Net Assets
Years Ended December 31, 2025 and 2024

(in thousands)	2025	2024
Net assets without donor restrictions		
Excess of revenues over expenses	$ 456,861	$ 317,461
Noncontrolling interest	(183)	-
Equity transfers to related parties	(44,606)	(157,918)
Change in funded status of benefit plans	26,294	16,018
Net assets released from restrictions for capital purposes	26,818	21,006
Government grants used for capital purchases	13,792	54,958
Increase in net assets without donor restrictions	478,976	251,525
Net assets with donor restrictions		
Contributions	42,078	43,809
Investment income	4,213	2,033
Change in net unrealized gain	3,841	3,948
Net assets released from restrictions for operations	(16,713)	(15,827)
Net assets released from restrictions for capital purposes	(26,818)	(21,006)
Increase in net assets with donor restrictions	6,601	12,957
Increase in net assets	485,577	264,482
Net assets		
Beginning of year	3,688,402	3,423,920
End of year	$ 4,173,979	$ 3,688,402

The accompanying notes are an integral part of these consolidated financial statements.

AHS Hospital Corp.
Consolidated Statements of Cash Flows
Years Ended December 31, 2025 and 2024

(in thousands)	2025	2024
Cash flows from operating activities		
Change in net assets	$ 485,577	$ 264,482
Adjustments to reconcile change in net assets to net cash provided by operating activities		
Change in funded status of benefit plans	(26,294)	(16,018)
Equity transfers to related parties	44,606	157,918
Depreciation and amortization	193,484	183,188
Loss on disposal of property, plant and equipment	2,800	129
Noncontrolling interest	(183)	-
Net realized and unrealized gains on investments	(252,813)	(146,537)
Change in value of swap agreements	(705)	(1,573)
Amortization of deferred financing costs and bond premiums	(2,352)	(2,352)
Amortization of right of use assets	52,119	48,250
Grants and contributions restricted for capital purposes and permanent investments	(37,061)	(78,989)
Changes in assets and liabilities		
Increase in net patient accounts receivable	(3,813)	(81,138)
Increase in other assets	(8,673)	(85,631)
Increase (Decrease) in accounts payable, accrued expenses, estimated amounts due to third party payers, accrued employee benefits and net lease liabilities	10,911	(19,887)
Net cash provided by operating activities	457,603	221,842
Cash flows from investing activities		
Purchases of investments	(2,038,602)	(1,686,151)
Proceeds from sales of investments	2,079,363	1,606,029
Repayment of loan to AHSIC	6,799	6,548
Loan issued to CentraState	-	(20,000)
Repayment of loan to CentraState	-	19,681
Contributions to venture capital private equity funds	(3,374)	(2,786)
Acquisition of Advanced Care Oncology & Hematology Associates	(2,195)	(9,511)
Additions to property, plant and equipment	(249,009)	(311,927)
Net cash used in investing activities	(207,018)	(398,117)
Cash flows from financing activities		
Proceeds from line of credit	-	200,000
Principal payments on line of credit	-	(200,000)
Principal payments on long-term debt	(16,784)	(16,133)
Equity transfers to related parties	(44,606)	(143,069)
Grants and contributions restricted for capital purposes and permanent investments	35,595	63,218
Net cash used in financing activities	(25,795)	(95,984)
Increase (Decrease) in cash and cash equivalents	224,790	(272,259)
Cash and cash equivalents		
Beginning of year	244,580	516,839
End of the year	$ 469,370	$ 244,580
Supplemental disclosure of cash flow information		
Cash paid for interest	$ 50,408	$ 56,198
Increase (Decrease) in accruals for acquisition of property, plant, and equipment	4,610	(9,026)
Right of use assets obtained in exchange for operating lease obligations	33,009	99,646
Noncash equity transfers to related parties	-	14,849

The accompanying notes are an integral part of these consolidated financial statements.

(in thousands)

1. Organization

AHS Hospital Corp. and subsidiaries (the "Hospital") is a New Jersey not-for-profit entity comprised of five hospital facilities, the Atlantic Health Morristown Medical Center ("AHMMC"), the Atlantic Health Overlook Medical Center ("AHOMC"), the Atlantic Health Newton Medical Center ("AHNMC"), the Atlantic Health Chilton Medical Center ("AHCMC"), and the Atlantic Health Hackettstown Medical Center ("AHHMC"). Atlantic Visiting Nurse ("AVN"), which provides comprehensive home health and hospice and palliative care services as well as adult day care services and various community health services, is also included within the Hospital. Each of the above operate as divisions within AHS Hospital Corp. and not as separate corporations. Also, included in the Hospital is the Foundation for the Morristown Medical Center ("MMCF"), a wholly owned subsidiary and not-for-profit fundraising organization. The Hospital is exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code.

The Hospital provides regional health care services including a broad range of adult, pediatric, obstetrical/gynecological, psychiatric, oncology, intensive care, cardiac care and newborn acute care services to patients from the counties of Morris, Essex, Passaic, Sussex, Bergen, Hunterdon, Union, Warren and Somerset in New Jersey, Pike County in Pennsylvania and southern Orange County in New York. The Hospital is also a regional health trauma center that provides tri-state coverage and provides numerous outpatient ambulatory services, rehabilitation and skilled care and emergency care.

Also included in the Hospital is Practice Associates Medical Group doing business as Atlantic Medical Group, P.A. ("AMG"), the captive physician practice serving all of the Hospital divisions. It is a nonprofit corporation and an organization described in Section 501(c)(3) of the Internal Revenue Code. Originally formed to provide billing and collection services for fees generated by physicians employed by the hospital divisions, AMG now serves as a physician-governed group practice entity with over 1,800 providers. AMG supports the Hospital by improving consistency, enhancing collaboration among those delivering care and optimizing care system operations.

MMCF solicits funds in its general appeal to primarily support AHMMC and the community as MMCF's Board may deem appropriate. The by-laws of MMCF were amended on November 19, 2015, to provide that funds received by MMCF after the date of the amendment may be used for the benefit of Atlantic Health System, Inc. ("Atlantic Health") and the Hospital, including all subsidiaries, upon approval of the Executive Committee of the Board of MMCF.

In June 2019, Atlantic Rehabilitation Institute ("ARI") began operations under a joint venture between the Hospital and Lifepoint Health ("Lifepoint") (formerly Kindred Healthcare). ARI is a two-story, 38-bed rehabilitation facility, located in Madison, NJ and provides patient-focused rehabilitation dedicated to the treatment and recovery of individuals through intensive specialized rehabilitation services for patients who have experienced a loss of function from an injury or illness. The Hospital contributed the existing rehabilitation business for a 55% ownership investment. The Hospital consolidates the joint venture's operations and records an adjustment for the noncontrolling interest within other changes in net assets without donor restrictions on the consolidated statements of operations and separates Lifepoint's ownership as net assets attributable to noncontrolling interest within net assets without donor restrictions on the consolidated balance sheets.

(in thousands)

The Hospital is a wholly controlled subsidiary of Atlantic Health, a not-for-profit organization. Atlantic Health wholly owns the following for-profit entities; Atlantic Health Management Corp., a for-profit holding company, which owns AHS Investment Corporation and Subsidiaries ("AHSIC"); AHS Insurance Company, Ltd. (the "Captive"), a for-profit insurance company licensed under the provisions of the Cayman Islands Insurance Law; Atlantic Health Organization, LLC and AHS Health Network LLC, for-profit companies established to provide a vehicle to report risk contracting under the requirements of the banking and insurance regulations; Primary Care Partners, LLC, Atlantic Health Partners, LLC, and Atlantic Brain and Spine, LLC, for-profit physician practice entities; AHS ACO, LLC, Care Better ACO LLC and Premier Health ACO, LLC, for-profit limited liability companies established for the purpose of participating in the Medicare Shared Savings Program under the Patient Protection and Affordable and Accountable Care Act of 2010 as well as participating in shared savings programs with certain commercial carriers; and several urgent care and advanced urgent care centers located within the Hospital's geographic regions. AHSIC holds real estate interests and manages health care businesses including magnetic resonance imaging, durable medical equipment and private duty home care services. The Captive's principal activity is to provide for professional and commercial general liability insurance to Atlantic Health and its subsidiaries beginning January 1, 2002. In addition, Atlantic Health wholly owns the following not-for-profit entities: Atlantic Ambulance Corp., a not-for-profit company established to provide emergency and nonemergency medical transportation to Atlantic Health and its subsidiaries; North Jersey Health Care Properties which owns commercial buildings; Prime Care, Inc. which provides various wellness, health education and other health services; and Newton Medical Center Foundation, Inc. and the Chilton Medical Center Foundation, Inc., both not-for-profit fund raising organizations for the benefit of their respective Hospital Divisions.

The Overlook Foundation and the Foundation for the Hackettstown Medical Center are not-for-profit fundraising organizations affiliated with the AHOMC and AHHMC, respectively, however, they are not controlled subsidiaries of Atlantic Health or the Hospital.

Effective January 1, 2022, Atlantic Health and CentraState Healthcare System ("CentraState"), a nonprofit health system with a continuum of care operating one acute care hospital in Freehold, New Jersey in Monmouth County, completed their newly expanded partnership, creating a unique model for health system co-ownership under which Atlantic Health became the 51% majority corporate member in CentraState and CentraState joined the System's network of care. The partnership is structured to deliver benefits to patients, physicians, and caregivers in CentraState's communities by strengthening its integrated clinical services, physician network and infrastructure through capital investments.

In January 2024, Atlantic Health and Saint Peter's Healthcare System ("SPHS") signed a Letter of Intent to establish a strategic partnership, subsequently a Member Substitution Agreement in June 2024. After extensive discussions and a thorough analysis of the rapidly evolving health care landscape, Atlantic Health and SPHS announced on October 6, 2025, their mutual agreement not to move forward with the transaction.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements have been prepared on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America ("GAAP").

(in thousands)

The consolidated financial statements include the accounts of its controlled subsidiaries MMCF and AMG. All significant intercompany balances and transactions are eliminated in consolidation.

Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to contractual discounts for patient service revenue, third party payer settlements, self-insurance liabilities, investment valuation and accrued employee benefits. Actual results may differ from those estimates.

Cash and Cash Equivalents
Cash and cash equivalents include highly liquid short-term investments with original maturities of three months or less from the date of acquisition. The Hospital elected to treat highly liquid short-term investments held within its assets limited as to use and long-term investments and other assets financial statement line items as investments and therefore exclude them from cash and cash equivalents in the consolidated statements of cash flows. As of December 31, 2025 and 2024, the Hospital did not have any restricted cash.

At December 31, 2025 and 2024, the Hospital had cash balances in a financial institution that exceeded federal depository insurance limits. Management believes that the credit risk related to these deposits is minimal.

The following is a reconciliation of cash and cash equivalents reported on the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.

	2025	2024
Cash and cash equivalents	$ 394,370	$ 244,580
Cash included in assets limited as to use and investments	75,000	-
Total cash and cash equivalents shown in the consolidated statements of cash flows	$ 469,370	$ 244,580

Assets Limited as to Use and Investments
Assets limited as to use principally consist of short-term investments including money market funds held by a trustee under the bond indenture agreement and funds set aside by the Board of Trustees over which the Board of Trustees retains control and may, at its discretion, subsequently use for other purposes. Amounts required to meet current debt service payments of the Hospital have been classified as current in the consolidated balance sheets at December 31, 2025 and 2024.

Investments in equity securities with readily determinable fair values and all investments in debt securities are measured at fair value in the consolidated balance sheets. Investment income or loss, including realized gains and losses on investments, interest and dividends, and unrealized

gains and loss, is included within nonoperating activities within the consolidated statements of operations, unless the income or loss is restricted by donor or law.

Beneficial Interest in Perpetual Trusts
The Hospital has been designated the beneficiary under certain perpetual trusts. The Hospital recognizes contribution revenue at the time an irrevocable trust is created at the fair value of the trust's assets. The contribution revenue is classified as net assets with donor restrictions. The Hospital revalues its interest in the perpetual trusts annually and reports any gain or loss as change in net unrealized gain (loss) from net asset with donor restrictions in the consolidated statement of changes in net assets. The underlying investments held in trust are held primarily in equity securities with readily determinable fair value. Income earned on the trust assets is included within nonoperating gains, net in the consolidated statements of operations.

Other Current Assets
Included within other current assets in the consolidated balance sheets are amounts due from related parties, prepaid expenses, and inventory.

Inventories
Inventories, primarily supplies, are included in other current assets and are stated at the lower of cost or net realizable value using the first-in, first-out method.

Property, Plant and Equipment
Property, plant and equipment are stated at cost. The Hospital provides for depreciation of land improvements, buildings and improvements, and equipment on a straight-line basis over the asset's estimated useful life. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are reversed from the accounts, and any gain or loss is recorded in operations. Repairs and maintenance expenditures are expensed as incurred.

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future net cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2025 and 2024, there were no events that would indicate an impairment of long-lived assets.

Gifts of long-lived assets such as property, plant and equipment are recorded at the fair value at the date of the gift and reported as an increase to net assets without donor restrictions unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as contributions with donor restriction in the consolidated statements of changes in net assets. Absent explicit donor stipulations about how long those long-lived assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

Leases
The Hospital leases certain office and distribution facilities ("real estate"), as well as medical and other equipment, which are all accounted for under FASB Accounting Standards Codification ("ASC") 842, *Leases*. The Hospital has made an accounting policy election to not apply recognition

requirements of ASC 842 to short-term leases, which are those leases with a term of one year or less.

The Hospital considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether to renew or replace a real estate lease. Real estate agreements, which expire at various dates through 2040, often include renewal options, either at fixed rents or subject to a fair value assessment at the time of exercise. Real estate renewal options are included in the measurement of right of use asset and lease liabilities when the exercise of such options is reasonably certain. Equipment renewal options are excluded from the lease term because they are not reasonably certain to be renewed due to rapid technology changes.

There is generally no readily determinable discount rate implicit in the Hospital's leases. Accordingly, the Hospital uses its incremental borrowing rate throughout the term of the lease, unless there is a modification, at which time, the rate may be updated with a more current incremental borrowing rate.

For real estate leases, the Hospital's accounting policy election is to separate lease and nonlease components. The Hospital includes the following as lease components when determining its real estate lease payments: fixed rent, predetermined rent escalations and rent-free periods. The Hospital recognizes rent expense on a straight-line basis over the related terms of such leases, beginning from when the Hospital takes possession of the asset. Variable rents resulting from adjustments to consumer price indices are recorded in the periods such amounts are adjusted and determined. Variable expenses are considered nonlease components and are expensed as incurred.

For equipment leases, the Hospital's accounting policy election is to not separate lease and nonlease components. Equipment lease agreements, including medical equipment, contain one fixed payment amount associated with the lease of the equipment, as well as maintenance, repairs, customer support, and training. Certain medical equipment leases also contain minimum purchases of consumables, which are considered in-substance fixed lease payments. The Hospital bundles its equipment lease payments. Lease expense is recognized on a straight-line basis over the related terms of such agreements.

Net Assets

Net assets without donor restrictions are derived from gifts that are not subject to explicit donor-imposed restrictions. Resources arising from the results of operations or assets set aside by the Board of Trustees are classified as without donor restrictions for external reporting purposes.

Net assets with donor restrictions are those funds whose use by the Hospital has been limited by donors to a specific time period and/or purpose. Once the restrictions are satisfied, or have been deemed to have been satisfied, those assets with donor restrictions are released from restrictions. Certain donor restrictions are perpetual in nature and the income from those funds is expendable to support various healthcare services or projects. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions. Management of the Hospital has interpreted the State of New Jersey's enacted version of the Uniform Prudent Management of Institutional Funds Act ("UPMIFA") as requiring the preservation of the historic dollar value of donor-restricted endowment funds (absent explicit donor stipulations to the contrary). Historic dollar value is defined as the aggregate fair value in dollars of (i) an

(in thousands)

endowment fund at the time it became an endowment, (ii) each subsequent donation to the fund at the time it is made, and (iii) each accumulation made pursuant to a direction in the applicable gift instrument at the time the accumulation is added to the fund. Based on this interpretation, the Hospital classifies as net assets with donor restrictions: (a) the original value of gifts donated to the restricted net assets, (b) the original value of subsequent gifts to the permanent endowment, (c) the net realizable value of future payments to restricted net assets in accordance with the donor's gift instrument (outstanding endowment pledges net of applicable discount), and (d) appreciation (depreciation), gains (losses) and income earned on the fund when the donor states that such increases or decreases are to be treated as changes in net assets with donor restrictions. The remaining portions of the donor-let restricted endowment fund that is not classified in net assets with donor restrictions in perpetuity is classified as net assets with donor restrictions until those amounts are appropriated for expenditure by the Hospital in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the Hospital considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

(1) The duration and preservation of the fund.

(2) The purpose of the organization and the donor-restricted endowment fund.

(3) General economic conditions.

(4) The possible effect of inflation and deflation.

(5) The expected total return from income and the appreciation of investments.

(6) Other resources of the Hospital; and

(7) The investment policies of the Hospital.

The Hospital has a policy of appropriating for distribution each year up to 5% of its endowment fund's average fair value over the prior 12 quarters through the calendar year end preceding the fiscal year in which the distribution is planned. In establishing this policy, the Hospital considered the long-term expected return on its endowment. This is consistent with the Hospital's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term as well as to provide additional real growth through new gifts and investment return. This method also compensates for any volatile year-to-year fluctuation in investment returns.

Management further understands that expenditures from a donor-restricted fund is limited to the uses and purposes for which the endowment fund is established and the use of net appreciation, realized gains (with respect to all assets) and unrealized gains (with respect only to readily marketable assets) is limited to the extent that the fair value of a donor-restricted fund exceeds the historic dollar value of the fund (unless the applicable gift instrument indicates that net appreciation shall not be expended), to the extent that such expenditure is prudent, considering the long and short term needs of the Hospital in carrying out its purposes, its present and anticipated financial requirements, expected total return on its investments and general economic conditions. Under the policies established and approved by the Hospital's Finance and Investment Committee, donor-restricted endowment funds are invested in income-generating investment vehicles to generate appreciation and preserve capital.

(in thousands)

Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. The gifts are reported as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified as net assets without donor restrictions and reported in the consolidated statements of operations as net assets released from restrictions.

Net Patient Service Revenue and Patient Accounts Receivable
Net patient service revenue is reported at the amount that reflects the consideration to which the Hospital (including AMG and AVN) expects to be entitled in exchange for providing patient care. These amounts are net of appropriate discounts to give recognition to differences between the Hospital's charges and reimbursement rates from third party payers. The Hospital is reimbursed from third party payers under various methodologies based on the level of care provided. Physician services are billed at professional rates tied to contracts for visits and procedures done in the physician office setting. Certain net revenues received are subject to audit and retroactive adjustment for which amounts are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined. The net amounts recorded, related to prior years and changes in estimates, increased net patient service revenue by $19,974 and $30,577 for the years ended December 31, 2025 and 2024, respectively.

Revenue is recognized as performance obligations are satisfied. The Hospital determines performance obligations based on the nature of the services provided. The Hospital recognizes revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. Generally, performance obligations satisfied over time relate to patients in the Hospital receiving inpatient acute care services. The Hospital measures performance obligations from admission to the point when there are no further services required for the patient, which is generally the time of discharge. The Hospital recognizes revenues for performance obligations satisfied at a point in time, which generally relate to patients receiving outpatient services including physician practices, when: (1) services are provided; and (2) when there is no expectation that the patient requires additional services.

Because the Hospital's patient service performance obligations related to contracts with a duration of less than one year, the Hospital has elected to apply the optional exemption provided in FASB ASC 606, *Revenue from Contracts with Customers* and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Hospital determines the transaction price based on gross charges for services provided, reduced by the contractual adjustments provided to third party payers, discounts provided to uninsured patients in accordance with the Hospital's policy, and implicit price concessions provided to uninsured patients. The Hospital determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Hospital determines its estimate of implicit price concessions based on its historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The consolidated

financial statement effects of using this practical expedient are not materially different from an individual contract approach.

In general, patients who are covered by third party payers are responsible for related co-pays co-insurance and deductibles, which vary in amount. The Hospital also provides services to uninsured patients and offers uninsured patients a discount from standard charges. Then the Hospital estimates the transaction price for patients with co-pays, co-insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under the Hospital's uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual discount, which reduces net patient service revenue at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual discounts recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self-pay accounts and other factors that affect the estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of the change.

A summary of the payment arrangements with major third-party payers is as follows:

Medicare
Inpatient acute care, behavioral care and rehabilitation services and most outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates per discharge. These rates vary according to a patient classification system that is based on clinical, diagnostic and other factors. The Hospital is reimbursed for certain reimbursable items at a tentative rate with final settlement determined after submission of the annual cost report by the Hospital and audits thereof by the Medicare administrative contractor. The Hospital's classification of patients under the Medicare program and the appropriateness of their admission are subject to an independent review by a peer review organization under contract with the Hospital. The Hospital's Medicare cost reports have been audited and finalized by the Medicare administrative contractor through December 31, 2022 for AHMMC, AHCMC, and AHHMC, and 2021 for the AHNMC and AHOMC.

Medicaid
Inpatient acute care services rendered to Medicaid program beneficiaries are paid at prospectively determined rates per discharge. These rates vary according to a patient classification system that is based on clinical, diagnostic and other factors. Outpatient services are paid based upon a cost reimbursement methodology and certain services are paid based on a Medicaid fee schedule. The Hospital is paid for reimbursable costs at a tentative rate with final settlement determined after submission of the annual cost report by the Hospital and audit thereof by the Medicaid fiscal intermediary. The Hospital's Medicaid cost reports have been audited and finalized by the Medicaid fiscal intermediary through December 31, 2022 for AHNMC, AHCMC and AHHMC, and through December 31, 2023 for AHMMC and AHOMC.

Managed Care, Commercial and Other
The Hospital has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis for payment to the Hospital under these agreements includes prospectively determined rates per day/case and discounts from established charges.

(in thousands)

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Noncompliance includes fines, penalties and exclusion from the Medicare and Medicaid programs. The Hospital has established a Corporate Compliance Program to monitor and maintain compliance with various regulations.

Other Revenue
Included within other revenue in the consolidated statements of operations are those amounts the Hospital derives from cafeteria sales, parking lot revenue, and various other miscellaneous receipts. Additionally, the Hospital recorded $26,172 in other revenue for the Employee Retention Credit, a refundable federal payroll tax credit created during Covid-19 under the CARES Act, during the year ended December 31, 2025.

Performance Indicator
The consolidated statements of operations include excess of revenues over expenses as the performance indicator. Changes in net assets without donor restrictions which are excluded from excess of revenues over expenses, consistent with industry practice, include noncontrolling interest, equity transfers to related parties, changes in funded status of benefit plans, net assets released from restrictions for capital purposes, and government grants used for capital purchases. The Hospital differentiates its operating activities through the use of income from operations as an intermediate measure of operations. For the purposes of display, investment income, net, changes in unrealized gains on investments, and other nonoperating items (which include changes in the value of swap agreements and other components of net periodic benefit costs), which the Hospital does not consider to be a component of its operating activities are excluded from the income from operations in the consolidated statements of operations.

Fair Value
FASB ASC 820, *Fair Value Measurements*, establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value requires an organization to determine the unit of account, the mechanism of hypothetical transfer, and the appropriate markets for the asset or liability being measured.

The guidance establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the reporting entity and unobservable inputs reflect the entities own assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

(in thousands)

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the Hospital for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

Level 1 Quoted market prices in active markets for identical assets or liabilities. Level 1 assets consist of short-term investments, including money market funds and common stock, as they are traded in an active market with sufficient volume and frequency of transactions.

Level 2 Quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability. Level 2 assets consist of money market funds and mutual funds that are nonexchange traded and valued based on net asset values (NAV) calculated by the funds' independent administrators which are calculated at least daily. These valuations are readily observable in the marketplace or are supported by observable levels at which transactions are executed in the marketplace. As Level 2 investments include positions that are not traded in active markets and/or are subject to transfer restrictions, valuations may be adjusted to reflect illiquidity and /or no transferability, which are generally based on available market information. Redemptions from each of the funds can be made at least daily on the latest reported NAV.

Level 3 Unobservable inputs for the asset or liability that are supported by little or no market activity and that are significant to the fair value. Level 3 assets consist of beneficial interests in perpetual trusts held by third parties, primarily invested in equities and fixed income securities.

For investments in alternative investments, fair value is measured based on unobservable inputs that cannot be corroborated by observable market data. The Hospital accounts for these investments within its long-term investment portfolio using the NAV as a practical expedient, and as such these investments are excluded from the fair value hierarchy.

Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:

Market Approach (M) - Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Cost Approach (C) - Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and

Income Approach (I) - Techniques to convert future amounts to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Inputs are used in applying the various valuation techniques and broadly refer to the assumptions the market participants use to make valuation decisions. Inputs may include price information, credit data, liquidity statistics and other

(in thousands)

factors. The Hospital utilized the best available information in measuring fair value (Notes 6 and 10).

Reclassifications
Certain previously reported amounts in the fiscal 2024 consolidated financial statements have been reclassified in order to conform to fiscal year 2025 presentation.

3. Charity Care

The Hospital provides care to patients who meet certain criteria defined by the New Jersey Department of Health and Senior Services ("DOHSS") without charge or at amounts less than its established rates. The Hospital maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges foregone for services and supplies furnished. The Hospital receives partial reimbursement for the uncompensated care it provides Note 4). The estimated amount of charity care provided at cost under DOHSS guidelines during the years ended December 31, 2025 and 2024 amounted to approximately $156,854 and $140,318, respectively.

The estimated charity care cost is based on the calculation of a ratio of cost to gross charges, and then multiplying that ratio by the gross charges foregone for providing charity care (i.e. charity care discounts).

4. Net Patient Service Revenue

The components of net patient service revenue for the Hospital (including AVN and AMG) for the years ended December 31, 2025 and 2024 are as follows:

	2025	2024
Gross charges		
Inpatient	$ 10,610,667	$ 9,621,267
Outpatient	11,372,222	10,069,440
Physician practices	1,766,046	1,563,778
Total gross charges	23,748,935	21,254,485
Net additions (deductions) from gross charges		
Contractual discounts and implicit price concessions	(18,848,706)	(16,791,535)
Charity care discount	(190,332)	(172,351)
Subsidies from State of New Jersey		
County Option Hospital Fee Program	22,343	-
Special subsidy	359	359
Graduate Medical Education	10,441	9,995
Charity care and medicaid managed care add-on	9,638	7,428
Total net additions (deductions from gross charges)	(18,996,257)	(16,946,104)
Net patient service revenue	$ 4,752,678	$ 4,308,381

Commencing July 1 2025, the Hospital receives additional Medicaid funding under the New Jersey County Option Hospital Fee Program. This program is administered through the New Jersey

(in thousands)

Department of Human Services-Division of Medical Assistance and Health Services. The program requires that participating hospitals pay quarterly assessed fees based on estimated non-Medicare discharge data within the county, and such payments are then pooled with federal Medicaid matching funds and redistributed to the participating hospitals as State Directed Payments. The State Directed Payments are subject to annual settlement based on actual Medicaid utilization data and other factors. The program resulted in fees accrued by the Hospital of $10,826 in the year ended December 31, 2025. The Hospital recognized subsidies totaling $22,343 in net patient service revenue in the year ended December 31, 2025.

The Hospital recorded $118,282 and $159,733 of implicit price concessions as a direct reduction of patient service revenues during the years ended December 31, 2025 and 2024, respectively.

The mix of Hospital net patient service revenue (excluding net revenue recorded by AMG), net of contractual discounts and implicit price concessions by payer for the years ended December 31, 2025 and 2024 is as follows:

	2025	2024
Medicare	22.6 %	24.4 %
Medicaid	0.8	1.0
Managed care and other third party payers	75.4	73.1
Self pay	0.2	1.0
State Subsidies	1.0	0.5
	100.0 %	100.0 %

Net patient service revenue recorded by AMG's physician practices amounted to $665,613 and $566,467 for the years ended December 31, 2025 and 2024, respectively. AMG's net patient service revenue by payer for the years ended December 31, 2025 and 2024, is as follows:

	2025	2024
Medicare	25.4 %	22.7 %
Medicaid	0.4	0.4
Managed care and other third party payers	74.1	76.7
Self pay	0.1	0.2
	100.0 %	100.0 %

(in thousands)

5. Concentration of Credit Risk

The Hospital extends credit without collateral to its patients, most of whom are local residents and are insured under third-party payer agreements. Accounts receivable net of contractual discounts and implicit price concessions from patients and third-party payers, as of December 31, 2025 and 2024, were as follows:

	2025	2024
Medicare	19.7 %	17.2 %
Medicaid	2.1	2.5
Managed care and other third party payers	70.6	71.4
Self pay	7.6	8.9
	100.0 %	100.0 %

6. Assets Limited as to Use, Long-Term Investments and Other Assets

Assets limited as to use at December 31, 2025 and 2024 consist of the following:

	2025	2024
Board designated for capital and program costs		
Cash held for investments	$ 75,000	$ -
Short-term investments including money market funds	223,409	254,899
Equity securities	413,232	416,132
Fixed income funds	740,000	648,941
Mutual funds	1,499,935	1,542,043
Investments measured at net asset value	181,833	-
Alternative investments - equity	-	28
	3,133,409	2,862,043
Under bond indenture agreements		
Short-term investments including money market funds		
Interest account	2,850	3,167
Principal account	4,063	6,949
Debt service reserve fund	646	671
	7,559	10,787
Total assets whose use is limited	3,140,968	2,872,830
Less: Assets limited as to use and are required for current liabilities	61,443	67,872
Noncurrent assets limited as to use	$ 3,079,525	$ 2,804,958

Assets limited as to use under bond indenture agreements represent certain funds that are controlled by trustees for as long as any of the bonds remain outstanding. These funds, including

(in thousands)

interest income, are held by bank trustees who administer the trusts as required under the bond indenture agreements.

Long-term investments and other assets, at December 31, 2025 and 2024, are as follows:

	2025	2024
Long-term investments		
Short term investments including money market funds	$ 9,613	$ 4,703
Mutual funds	88,844	82,423
Alternative investments - equity	8,534	7,946
	106,991	95,072
Other assets		
AHSIC related party loans	107,407	112,200
Professional and general liability insurance recoveries	116,680	118,516
CentraState related party loans	113,816	113,816
Workers compensation liability insurance recoveries	11,300	8,300
Accrued employee benefit asset (Note 10)	43,200	37,841
Due from Overlook Foundation	40,336	40,481
Due from Newton Medical Center Foundation	3,864	3,385
Due from Chilton Medical Center Foundation	7,009	6,407
Due from the Foundation for Hackettstown Medical Center	2,621	2,328
Venture capital private equity funds	27,627	24,253
Equity method investments	4,153	3,842
Beneficial interest in trusts	3,003	2,634
Goodwill	44,321	14,633
Life interest in real estate	9,775	9,000
Other	8,253	8,918
	543,365	506,554
Total long-term investments and other assets	$ 650,356	$ 601,626

On August 17, 2022, the Hospital entered into a secured loan agreement with CentraState in the amount of $103,497, whereby the proceeds were utilized by CentraState to pay off or legally defease all of its financed obligations as of that date. CentraState will pay interest to the Hospital monthly at a fixed rate of 3.21% with the full principal amount due to the Hospital on May 31, 2037. The loan is collateralized by the gross receipts of CentraState as well as its owned properties. In addition, certain financial covenants must be maintained by CentraState. On July 1, 2024, CentraState sold the Center for Aging, Inc. d/b/a Applewood, its wholly owned subsidiary to an unrelated entity. Upon sale, CentraState transferred $19,681 to the Hospital to pay off the portion of the secured loan related to Applewood.

On August 31, 2023, the Hospital entered into a revolving credit loan agreement with CentraState in the amount of $30,000, whereby drawdowns were utilized by CentraState to pay working capital requirements to meet its obligations. CentraState will pay interest to the Hospital monthly at a fixed annual rate of 5% with the full principal amount due to the Hospital on August 31, 2028. At

(in thousands)

December 31, 2025 and 2024, CentraState's outstanding drawn down on the revolving credit loan, was $30,000.

On February 5, 2024, Advanced Care Oncology & Hematology Associates physician practice and oral pharmacy was acquired. There was an initial payment made to the sellers on the closing date and three subsequent annual installment payments to be made on the anniversary of the closing date subject to the practice maintaining or exceeding annual aggregate productivity thresholds. The total purchase price represents the fair market value of the purchased interest which was validated by an independent, third-party appraisal. The related goodwill was recorded in long-term investments and other assets.

The Hospital accrues an estimate of the ultimate cost of claims under all insurance policies whether the policy is fully insured or a self-insurance policy, with any insurance recoverable under such policies recorded as a receivable. As of December 31, 2025 and 2024, the Hospital has recorded a corresponding liability for professional and general liability insurance claims within accounts payable and accrued expenses in the consolidated balance sheets (Note 11). As of December 31, 2025 and 2024, the Hospital recorded liabilities related to estimated gross workers compensation claims totaling $29,300 and $26,300, respectively, within accounts payable and accrued expenses in the consolidated balance sheets.

Due from Overlook, Newton, Chilton and Hackettstown Medical Center Foundations relate to the amounts due from the Foundations for contributions received by the Foundations on behalf of AHOMC, AHNMC, AHCMC and AHHMC. The Foundations solicit funds in their general appeal to support the Hospital and for other health care purposes as the respective Foundation's individual Board of Trustees may deem appropriate. In the absence of donor restrictions, the Foundations have discretionary control over the amounts to be distributed to the providers of health care services, the timing of such distributions, and the purposes for which such funds are used. The assets held at the affiliated foundations are comprised primarily of cash and cash equivalents, marketable equity securities and debt securities.

Investment income relating to long-term investments and assets limited as to use, excluding those held under bond indenture agreements and restricted funds, for the years ended December 31, 2025 and 2024 consist of the following:

	2025	2024
Interest and dividend income	$ 82,304	$ 79,172
Realized gains on sales of securities	141,418	71,230
Investment income	223,722	150,402
Change in net unrealized gains	103,341	69,325
Total investment return	$ 327,063	$ 219,727

(in thousands)

The fair value of the Hospital's financial assets that are measured on a recurring basis at December 31, 2025 and 2024 are as follows:

2025	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Fair Value December 31, 2025	Valuation Technique[1]
Assets limited as to use					
Cash held for investments	$ 75,000	$ -	$ -	$ 75,000	M
Short-term investments including money market funds	230,968	-	-	230,968	M
Equity securities	413,232	-	-	413,232	M
Fixed income funds	-	740,000	-	740,000	M
Mutual funds	-	1,499,935	-	1,499,935	M
	$ 719,200	$ 2,239,935	$ -	2,959,135	
Investments measured at net asset value				181,833	
				$ 3,140,968	
Long-term investments					
Short-term investments including money market funds	$ 9,613	$ -	$ -	$ 9,613	M
Mutual funds	-	88,844	-	88,844	M
	$ 9,613	$ 88,844	$ -	98,457	
Investments measured at net asset value				8,534	
				$ 106,991	
Life interest in real estate	$ -	$ -	$ 9,775	$ 9,775	M
Beneficial interests in perpetual and remainder trusts	$ -	$ -	$ 3,003	$ 3,003	M
Venture capital private equity funds	$ -	$ -	$ 27,627	$ 27,627	M

(in thousands)

2024	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Fair Value December 31, 2024	Valuation Technique[1]
Assets limited as to use					
Short-term investments including money market funds	$ 265,686	$ -	$ -	$ 265,686	M
Equity securities	416,132	-	-	416,132	M
Fixed income funds	-	648,941	-	648,941	M
Mutual funds	-	1,542,043	-	1,542,043	M
	$ 681,818	$ 2,190,984	$ -	2,872,802	
Investments measured at net asset value				28	
				$ 2,872,830	
Long-term investments					
Short-term investments including money market funds	$ 4,703	$ -	$ -	$ 4,703	M
Mutual funds	-	82,423	-	82,423	M
	$ 4,703	$ 82,423	$ -	87,126	
Investments measured at net asset value				7,946	
				$ 95,072	
Life interest in real estate	$ -	$ -	$ 9,000	$ 9,000	M
Beneficial interests in perpetual and remainder trusts	$ -	$ -	$ 2,634	$ 2,634	M
Venture capital private equity funds	$ -	$ -	$ 24,253	$ 24,253	M

(1) The three valuation techniques are market approach (M), cost approach (C), and income approach (I), as discussed in Note 2.

There was no significant Level 3 investment activity for the years ended December 31, 2025 and 2024.

(in thousands)

7. Property, Plant and Equipment

Property, plant and equipment at December 31, 2025 and 2024 are as follows:

	2025	2024	Depreciable Life *(in Years)*
Land	$ 66,562	$ 66,562	
Land improvements	4,377	8,210	5-45
Buildings and improvements	2,167,487	1,949,739	10–50
Equipment and fixed equipment	1,996,404	1,906,178	3–25
Construction in progress	139,334	230,657	
	4,374,164	4,161,346	
Less: Accumulated depreciation	2,821,853	2,626,442	
Property, plant and equipment, net	$ 1,552,311	$ 1,534,904	

Depreciation expense for the years ended December 31, 2025 and 2024 was $193,484 and $183,188, respectively.

(in thousands)

8. Long-Term Debt

Long-term debt at December 31, 2025 and 2024 consists of the following:

	2025	2024
$100,000 JP Morgan Chase Taxable Term Loan maturing on May 31, 2037. Principal is payable quarterly as is interest at an annual interest rate of 3.21%. The loan is collateralized by the Hospital's gross receipts.	$ 88,333	$ 91,667
$450,000 Series 2021 Taxable Bonds (Fixed Rate) maturing on July 1, 2051. Interest is payable each January 1 and July 1 at an annual interest rate of 2.78%. The bonds are collateralized by the Hospital's gross receipts.	450,000	450,000
$224,800 New Jersey Health Care Facilities Financing Authority ("NJHCFFA"), AHS Hospital Corporation, Series 2016 Refunding Bonds (Fixed Rate), in varying maturities through 2041 at annual interest rates varying between 3.00% and 5.00%. Interest is payable each January 1 and July 1 and principal is payable each July 1 commencing in 2017. As of December 31, 2025, the average interest rate on the bonds was 4.14%. The bonds are collateralized by the Hospital's gross receipts.	134,055	146,925
$425,000 Series 2015 Taxable Bonds (Fixed Rate) maturing on July 1, 2045. Interest is payable each January 1 and July 1 at an annual interest rate of 5.02%. The bonds are collateralized by the Hospital's gross receipts.	425,000	425,000
$50,000 Bank of America Taxable Term Loan maturing on December 1, 2028. Interest is payable monthly at an annual interest rate of 5.60%. The loan is collateralized by the Hospital's gross receipts.	50,000	50,000
$177,110 NJHCFFA AHS Hospital Corporation, Series 2008A Revenue Bonds (Fixed Rate), in varying maturities through 2027 at annual interest rates varying between 4.88% and 5.00%. Interest is payable each January 1 and July 1 and principal is payable each July 1 commencing in 2009. As of December 31, 2025, the average interest rate on the bonds was 5.00%. The bonds are collateralized by the Hospital's gross receipts.	935	1,515
$177,110 NJHCFFA AHS Hospital Corporation, Series 2008B and 2008C Revenue Bonds (Variable Rate), in varying maturities commencing in 2027 through 2036 at annual interest rate of 3.08%. The interest on the bonds is payable monthly and principal will be payable each July 1. As of December, 31, 2025, the average interest rate on the bonds was 2.78%. The bonds are collateralized by the Hospital's gross receipts.	177,110	177,110
Total long-term debt	1,325,433	1,342,217
Unamortized bond premium	46,615	49,219
Deferred financing fees	(5,151)	(5,403)
	1,366,897	1,386,033
Less: Current portion of long-term debt	13,485	19,136
Long-term debt, net of unamortized bond premium, debt issuance costs, and current portion	$ 1,353,412	$ 1,366,897

(in thousands)

The Hospital is the sole member of the obligated group as defined in and established under the Master Trust Indenture. Neither Atlantic Health nor any of its affiliates is liable to make any payment with respect to the bonds or any other obligations under the Master Indentures. Under the terms of the Master Trust Indenture, the Hospital is required to maintain certain deposits with a trustee, which are included with assets limited as to use in the consolidated balance sheets. The Master Trust Indenture also contain provisions whereby certain financial ratios are to be maintained and permit additional borrowings subject to the maintenance of specific financial ratios. The most restrictive covenant is for the Hospital to maintain a debt service coverage ratio in each year of at least 1.2 times the debt service requirement on all long-term debt in that year. The Hospital is compliant with its financial covenants at December 31, 2025 and 2024.

On October 31, 2025, the Hospital entered into a second $200,000 revolving credit agreement with a commercial bank to provide for additional liquidity. The line is set to expire on October 30, 2026. It incurs interest at a rate of SOFR adjusted by 0.75% per annum on the amount drawn. Additionally, the line incurs a fee of 0.15% per annum on the unused portion of the line of credit. There were no amounts drawn on the line as of December 31, 2025. The line of credit contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants.

On May 31, 2022, the Hospital entered into a $100,000 taxable loan agreement with a commercial bank. The loan proceeds are to be used for general corporate purposes. Principal and interest, at a fixed rate of 3.21% on the outstanding balance, are due quarterly commencing September 1, 2022, with the remaining unpaid principal in the amount of approximately $50,833 due and payable on May 31, 2037. The agreement contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants. Subsequently, the Hospital entered into a secured loan agreement with CentraState to enable CentraState to pay off or legally defease all if its financed obligations as of that date (Note 7).

On January 27, 2021, the Hospital issued $450,000 Series 2021 Fixed Rate Taxable Bonds, the proceeds of which will be used for eligible corporate purposes of the Hospital and its affiliates. In addition, a portion of the proceeds were used to pay the costs of issuance. The Hospital also utilized the proceeds of the bonds to repay $50,000 that was outstanding on its $200,000 revolving line of credit. The agreement contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants.

On April 21, 2020, the Hospital entered into a $200,000 revolving credit agreement with a commercial bank to provide for additional liquidity. The line was set to expire on March 31, 2026. The line incurs interest at a rate of SOFR adjusted by 0.70% per annum on the amount drawn. Additionally, the line incurs a fee of 0.125% per annum on the unused portion of the line of credit. There were no amounts drawn on the line as of either December 31, 2025 or 2024. However, the Hospital drew down $200,000 on April 4, 2024 which was fully repaid by October 30, 2024. The line of credit contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants. On April 1, 2026, the Hospital renewed the line for an additional year.

In October 2016, the Hospital issued $224,800 Series 2016 Fixed Rate Tax-exempt Revenue Bonds through the NJHCFFA. The proceeds were used to refund a portion of the principal of its outstanding Revenue Bonds issued through the NJHCFFA in the amount of $114,255

(in thousands)

(Series 2008A) and $120,115 (Series 2011), and to pay all of the cost of issuance in the amount of $1,782. In addition, the NJHCFFA released $14,260 of the Hospital's debt service reserve fund in connection with the bond refunding to pay down a portion of the aforementioned outstanding principal on the Series' 2008A and 2011 bonds.

In May 2015, the Hospital issued $200,000 Series 2015 Fixed Rate Taxable Bonds, the proceeds of which are to be used for eligible corporate purposes of the Hospital and its affiliates. In addition, a portion of the proceeds were used to pay the costs of issuance. Effective August 2017, the Hospital executed a "tap" on the Series 2015 Fixed Rate Taxable Issuance for an additional $225,000. The Hospital received total proceeds of $268,023, which included a premium of $43,023. The agreement contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants.

In December 2013, the Hospital entered into a $50,000 taxable loan agreement with a commercial bank. The majority of the proceeds were used to legally defease AHCMC's NJHCFFA Series 2009 Revenue Bonds, which were assumed by the Hospital in 2014, concurrent with the merger. The agreement contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants.

In May 2008, the Hospital issued, through the NJHCFFA, $177,110 Series 2008A Revenue Bonds (Fixed Rate) and $177,110 Series 2008B and 2008C Revenue Bonds (Variable Rate), collectively referred to as the 2008 Bonds, to pay in full the Hospital's obligations under the interim method of financing enabling the Hospital to redeem all of its outstanding bond issues and terminate a portion of its related swaps for the Series 2003, 2004, 2006 and 2007 Revenue Bonds. The proceeds of the 2008 Bonds were also used to pay the costs of issuance of the 2008 Bonds. The Series 2006 and Series 2007 Revenue Bonds were issued in part to pay for the costs of certain capital projects of the Hospital and construction trustee funds were set up for disbursement for the payment of such costs. Amounts equal to the amounts on deposit in such construction funds were deposited with the trustee for the 2008 proceeds to complete those projects. In connection with the issuance of the Series 2016 Refunding Bonds noted above, $114,255 of the outstanding principal was refunded in October 2016.

The 2008 Variable Rate Bonds bear interest at weekly rates as determined by the remarketing agent. In the event that the purchase price of the corresponding Series of the Variable Bonds are not remarketed at the corresponding principal amount of such Series, the Variable Bonds are backed by a separate, irrevocable direct pay letters of credit by two banks, each expiring January 2029.

The future principal payments on long-term debt are as follows:

2026	$ 11,133
2027	6,038
2028	55,668
2029	182,578
2030	5,238
Thereafter	1,064,778
	$ 1,325,433

(in thousands)

Interest Swaps

On April 9, 2008, the Hospital unwound and reissued two new barrier swaps: the 2008 Swap and the 2004 Swap.

The 2008 Swap was reissued in place of the 2006A Swap when the Series 2006A Revenue Bonds were redeemed. This was a noncash transaction. The original notional amount of the swap was $91,550 subject to reduction in the principal amortization of a portion of the Hospital's Series 2008 variable rate debt and will expire on July 1, 2036, with an annual fee of 0.51%. The notional amount of the swap was $87,400 at December 31, 2025 and 2024. Under the terms of the swap agreement, if the Securities Industry and Financial Markets Association ("SIFMA"), formerly known as the Bond Market Association, Municipal Swap Index, exceeds 4.05% for 90 days, the Hospital will pay a fixed rate of 4.00% in addition to the annual fee of 0.51%. The Hospital will then receive 68% of SOFR and pay the counterparty 4.00%. Currently the swap is treated as an ineffective swap for accounting purposes until SIFMA exceeds 4.05% for 90 days, at that time the swap will be tested to determine if it qualifies as a cash flow hedge.

The 2004 Swap was reissued in place of the original 2004 Swap when the Series 2003 and 2004 Revenue Bonds were redeemed. This was a noncash transaction and there were no changes to the terms of the swap. The notional amount of the swap was $97,525, subject to reduction in the principal amortization of a portion of the Hospital's Series 2008 variable rate debt with an annual fee of 0.52%. The swap expired on July 1, 2025. The notional amount of the swap at December 31, 2024 was $5,175.

The following table presents the swap liabilities, recorded in accrued employee benefits and other, net of current portion, as of December 31, 2025 and 2024:

	2025	2024
2008 interest rate swap	$ 3,543	$ 4,232
2004 interest rate swap	-	16

The following table sets forth the effect of the interest rate swap agreements on the consolidated statements of operations for the years ended December 31, 2025 and 2024:

	Amount of Gain Recognized in the Performance Indicator	
	2025	2024
Derivative in nonhedging relationship		
Nonoperating gains, net		
2008 interest rate swap	$ 689	$ 1,531
2004 interest rate swap	16	42

In accordance with the above swap agreements, the Hospital is required to fund a cash collateral account if the market value of the combined swaps exceeds the trigger amount of $15,000 in 2025, or $12,000 in 2024. As of December 31, 2025 and 2024, the combined market value of the swaps was below the trigger and as such, no collateral was required by the counterparty.

(in thousands)

9. Leases

Lease expense recognized within supplies and other expenses in the consolidated statements of operations for the years ended December 31, 2025 and 2024 are as follows:

	2025	2024
Fixed operating lease expense	$ 61,167	$ 55,505
Short-term lease expense	5,574	6,721
Sublease income	(3,811)	(2,924)
Net lease expense	$ 62,930	$ 59,302

The weighted average lease terms and discount rates for the Hospital's operating leases for the years ended December 31, 2025 and 2024 are as follows:

	2025	2024
Weighted average remaining lease term (in years)		
Real estate leases	8.6	9.2
Equipment leases	2.8	3.5
Weighted average discount rate for operating leases	4.46 %	4.48 %

The following table provides supplemental cash flow information related to the Hospital's operating leases for the years ended December 31, 2025 and 2024:

	2025	2024
Cash paid for amounts included in the measurement of lease liabilities operating cash flows for operating leases	$ 65,534	$ 61,156
Right of use assets obtained in exchange for operating lease liabilities	33,009	99,646

(in thousands)

The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter to the operating lease liability recorded on the consolidated balance sheet for operating leases existing as of December 31, 2025:

2026	$	63,050
2027		56,840
2028		46,871
2029		42,399
2030		37,656
Thereafter		135,435
Total minimum lease commitments		382,251
Less: Imputed interest		43,496
Present value of lease liabilities		338,755
Less: Current portion of lease liabilities		51,294
Long-term lease liabilities	$	287,461

Minimum lease commitments after 2030 include $19,834 associated with renewal options that are reasonably certain to be exercised. Refer also to Note 13 for lease arrangements with related parties, which are included above.

10. Pension and Other Postretirement Benefit Plans

Defined Benefit Plans
The Hospital maintains a defined benefit cash balance pension plan (“Cash Balance Plan”) covering certain full-time employees, as well as various supplemental retirement plans, which provide pension benefits to certain key executives. Effective January 1, 2014, the Cash Balance Plan was frozen to new employees hired after December 31, 2013.

AHCMC had a noncontributory defined benefit retirement plan (“Chilton Plan”) covering substantially all of its full-time employees. Effective June 20, 2012, the Chilton Plan was frozen to all future benefits while preserving all benefits that had accrued as of June 30, 2012. AHCMC was required to fund the Chilton Plan for benefit obligations. As of December 31, 2014, the Chilton Plan merged its assets and liabilities with the Cash Balance Plan. The Hospital’s funding policy provides that payments to the Cash Balance Plan shall at least be equal to the minimum funding requirement of the Employee Retirement Income Security Act of 1974 (“ERISA”) plus additional amounts, which may be approved by the Hospital from time to time.

The Hospital sponsors three defined benefit postretirement plans AHMMC, AHOMC and formerly owned General Hospital Center at Passaic (the “General”). A description of the individual site plans are as follows:

- The AHMMC plan pays the cost of providing medical and life insurance postretirement benefits to employees and qualifying dependents (spouse or child) of the Hospital who retire under the retirement plan and meet the specified age and service requirements. Contributions were introduced beginning in 2003 for all current and future retirees.

(in thousands)

- The AHOMC plan provides postretirement medical benefits to eligible employees and their qualifying dependents (spouse or child). The benefits for services provided outside the Hospital are subject to deductibles and co-payments. There is no charge for services provided in the Hospital except for prescription drugs, which are charged at cost. In addition, the Hospital provides postretirement life insurance coverage for employees hired prior to July 2, 1995.

- The General plan provides for life insurance and medical benefits for certain employees retired as of July 1996, at which time the plan was amended to exclude all active employees who had not retired as of that date.

Both the AHMMC and AHOMC postretirement plans were amended in May 1996 to exclude new employees from participation.

The following tables provide a reconciliation of the changes in the plans' benefit obligation and fair value of assets for the years ended December 31, 2025 and 2024, a statement of the funded status of the plans and, the amounts recognized in the consolidated balance sheets as of December 31, 2025 and 2024.

	Pension Benefits		Other Postretirement Benefits	
	2025	2024	2025	2024
Accumulated benefit obligation	$ 899,316	$ 875,137	$ 134,597	$ 131,023
Change in benefit obligation				
Benefit obligation at beginning of year	$ 905,951	$ 921,650	$ 132,904	$ 134,597
Service cost	32,856	34,950	165	210
Interest cost	51,101	47,023	7,782	7,003
Plan participants' contributions	-	-	610	647
Actuarial loss (gain)	15,348	(35,561)	6,723	(2,366)
Benefits paid	(72,141)	(62,111)	(7,522)	(7,187)
Benefit obligation at end of year	933,115	905,951	140,662	132,904
Change in plan assets				
Fair value of plan assets at beginning of year	943,792	924,327	84,801	86,247
Actual return on plan assets	88,664	21,576	13,012	4,683
Medicare Part D subsidy	-	-	338	200
Employer contributions	16,000	60,000	229	211
Plan participants' contributions	-	-	610	647
Benefits paid	(72,141)	(62,111)	(7,522)	(7,187)
Fair value of plan assets at end of year	976,315	943,792	91,468	84,801
Funded status	$ 43,200	$ 37,841	$ (49,194)	$ (48,103)
Amounts recognized in the consolidated balance sheets consist of				
Current liabilities	$ -	$ -	$ (1,104)	$ (1,103)
Long-term assets (liabilities)	43,200	37,841	(48,090)	(47,000)
Accrued employee benefit asset (liabilities)	$ 43,200	$ 37,841	$ (49,194)	$ (48,103)
Amounts recognized in net assets without donor restrictions consist of				
Actuarial net loss	$ 193,210	$ 219,402	$ 4,932	$ 4,675
Prior service cost	973	1,332	-	-
	$ 194,183	$ 220,734	$ 4,932	$ 4,675

(in thousands)

The Cash Balance Plan discount rate decreased by 18 basis points in the current year and increased by 60 basis points in the prior year, resulting in an approximate $(12,800) loss and $44,400 gain in 2025 and 2024, respectively.

The following tables provide the components of the net periodic pension and other postretirement benefit costs and the total amount recognized in net periodic benefit cost and changes in net assets without donor restrictions for the years ended December 31, 2025 and 2024:

	Pension Benefits		Other Postretirement Benefits	
	2025	2024	2025	2024
Net periodic benefit cost				
Service cost	$ 32,856	$ 34,950	$ 165	$ 210
Interest cost	51,101	47,023	7,782	7,003
Expected return on plan assets	(59,921)	(56,826)	(5,873)	(5,197)
Actuarial loss (gain)	12,797	14,285	(742)	(804)
Amortization of prior service cost	359	359	-	-
Net periodic benefit cost	37,192	39,791	1,332	1,212
Amounts recognized in changes in net assets without donor restrictions				
Net (gain) loss	(26,551)	(14,955)	257	(1,063)
Total recognized in net periodic benefit cost and change in net assets without donor restrictions	$ 10,641	$ 24,836	$ 1,589	$ 149

The Hospital recorded the nonservice cost components of the net periodic benefit costs for its pension and postretirement benefit plans of $5,503 and $5,843 within nonoperating gains, net in the consolidated statements of operations for the years ended December 31, 2025 and 2024, respectively.

Assumptions used in determining the benefit obligations and net periodic benefit cost are as follows:

	Pension Benefits		Other Postretirement Benefits	
	2025	2024	2025	2024
Benefit obligations				
Discount rate	5.80 %	5.98 %	6.10 %	6.16 %
Rate of compensation increase	4.00	4.00	4.00	4.00
Net periodic benefit cost				
Discount rate	5.98 %	5.38 %	6.16 %	5.57 %
Expected return on plan assets	6.60	6.25	7.20	6.25
Rate of compensation increase	4.00	4.00	4.00	4.00

The postretirement plans assumed an annual rate of increase in the per capita cost of covered health care benefits of 8.50% and 7.75% for the years ended December 31, 2025 and 2024, respectively. The rate was assumed to decrease gradually to 4.04% for 2075 and remain at that level thereafter.

(in thousands)

The Cash Balance Plan's weighted average interest crediting rate assumption is 5.50% and 6.32% for all account balances for 2025 and 2024, respectively.

Expected Benefit Payments
The benefits expected to be paid in each year from 2026 to 2035 are:

		Other Postretirement Benefits	
	Pension Benefits	Without Medicare Subsidy	With Medicare Subsidy
2026	$ 112,491	$ 8,578	$ 8,183
2027	65,664	8,423	7,989
2028	70,895	9,136	8,663
2029	72,959	9,812	9,300
2030	73,884	10,442	9,895
2031-2035	403,954	58,630	55,488

The aggregate benefits expected to be paid are based on the same assumptions used to measure the benefit obligation at December 31, 2025 and include estimated future employee service.

Plan Assets
The Hospital considers multiple factors in establishing its multi-year expected return on plan assets assumption. These include but are not limited to its current asset allocation policy and target ranges by asset class; asset valuations; historical and projected rates of return by asset class; historical and projected correlations among asset classes; the opportunity to exceed passive index returns via active management through a combination of manager selection and alternative weightings among and within asset classes and the Hospital's historical performance experience.

The Hospital's investment objective is to achieve the highest reasonable total return after considering (i) plan liabilities, (ii) funding status and projected cash flows, (iii) projected market returns, valuations and correlations for various asset classes, and (iv) the Hospital's ability and willingness to incur market risk. The Hospital actively manages plan assets in order to add incremental returns by manager selection and asset allocation (increasing/decreasing allocations within allowable ranges based on current and projected valuations).

The Plans' weighted average asset allocations are as follows:

	Percentage of Plan Assets					
	Pension Benefits			Other Postretirement Benefits		
Asset Category	Target Allocation	2025	2024	Target Allocation	2025	2024
Equity securities	35-85%	22 %	23 %	55-80%	71 %	71 %
Debt securities	20-50%	26	27	10-30%	27	25
Other	0-25%	52	50	0-10%	2	4
		100 %	100 %		100 %	100 %

(in thousands)

The following tables summarize the Cash Balance Plan's financial instruments, which are measured at fair value on a recurring basis by caption and by level within the valuation hierarchy as of December 31, 2025 and 2024:

2025	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Fair Value December 31, 2025	Valuation Technique[(1)]
Plan assets					
Money market funds	$ 20,743	$ -	$ -	$ 20,743	M
Mutual funds	-	216,093	-	216,093	M
Fixed income funds	-	250,838	-	250,838	M
	$ 20,743	$ 466,931	$ -	487,674	
Investments measured at net asset value				488,641	
				$ 976,315	

2024	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Fair Value December 31, 2024	Valuation Technique[(1)]
Plan assets					
Money market funds	$ 8,981	$ -	$ -	$ 8,981	M
Mutual funds	-	217,657	-	217,657	M
Fixed income funds	-	254,283	-	254,283	M
	$ 8,981	$ 471,940	$ -	480,921	
Investments measured at net asset value				462,871	
				$ 943,792	

(1) The three valuation techniques are market approach (M), cost approach (C), and income approach (I), as discussed in Note 2.

The AHOMC and General postretirement plans are unfunded. The AHOMC plan has an aggregate benefit obligation of $5,000 and $4,932 at December 31, 2025 and 2024, respectively. The General plan has an aggregate benefit obligation of $637 and $636 at December 31, 2025 and 2024, respectively.

(in thousands)

The following tables summarize the AHMMC's postretirement plan's financial instruments, which are measured at fair value on a recurring basis by caption and by level within the valuation hierarchy as of December 31, 2025 and 2024:

2025	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Fair Value December 31, 2025	Valuation Technique[1]
Postretirement plan assets					
Money market funds	$ 2,040	$ -	$ -	$ 2,040	M
Mutual funds	-	89,428	-	89,428	M
	$ 2,040	$ 89,428	$ -	$ 91,468	

2024	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Fair Value December 31, 2024	Valuation Technique[1]
Postretirement plan assets					
Money market funds	$ 3,141	$ -	$ -	$ 3,141	M
Mutual funds	-	81,660	-	81,660	M
	$ 3,141	$ 81,660	$ -	$ 84,801	

(1) The three valuation techniques are market approach (M), cost approach (C), and income approach (I), as discussed at Note 2.

Expected Contributions
Based on the funded status of the Cash Balance Plan as of December 31, 2025, the Hospital expects to contribute $23,000 during fiscal year 2026. This will be evaluated on a quarterly basis. There are no required contributions to be made to the Hospital's other post-retirement plans.

Defined Contribution Plan
Effective January 1, 2014, new employees hired are eligible to participate in the Atlantic Health System 403(b) Retirement Savings Plan ("the 403(b) Plan"). For those eligible for matching contributions in the 403(b) Plan, the Hospital matches up to a percentage of compensation dependent on an employee's compensation, contribution and length of service. In addition, the Hospital provides a fixed nonelective contribution to the participants equal to 2 percent of compensation to participants employed at the end of the fiscal year. The Hospital contributed $55,141 and $46,866 to the 403(b) Plan for the years ended December 31, 2025 and 2024, respectively. Employees may contribute up to Internal Revenue code limits.

(in thousands)

11. Professional and General Liability Self Insurance

AHMMC, AHOMC, AHNMC, AHCMC (effective June 1, 2016), AHHMC (effective April 1, 2016), and AMG are covered by Atlantic Health for professional and commercial general liability through the Captive.

Under this plan, the Captive provides professional and commercial general liability coverage on a modified claims-made basis, with varying retroactive dates from November 1, 1994, for general liability and November 1, 1985, for professional liability. The per claim loss limits are $2,000 for each medical incident in respect of insured individuals, except for OBGYN medical professionals which are provided with $3,000 for each medical incident, $2,000 each general liability loss, and $250 per incident in respect of all other covered entities where charitable immunity in accordance with the provisions of the New Jersey statutory cap applies, with a $35,000 aggregate limit. The coverage for all other covered entities is limited to $10,000 without aggregate where the provisions of the cap do not apply. Effective June 1, 2025, the limits of the liability retained by the Captive pursuant to the professional and general liability policy have an aggregate of $37,500 and the maintenance retention for each loss settlement following erosion of the aggregate limit shall be $150. These policies were written on a claims-made basis. The policies were endorsed effective February 1, 2004, and for all subsequent underwriting periods to include the tail liability exposures attributable to prior periods, effectively making the policies occurrence basis coverage.

The Hospital obtained two renewable bank letters of credit for a total of $10,000 to support Atlantic Health's payable. The two letters of credit were subsequently combined into one $10,000 letter of credit, which is renewable annually. The Captive is the beneficiary of the letter of credit and can only draw down on the letter of credit, after the Captive's other assets are exhausted. As of December 31, 2025 and 2024, no amounts are outstanding under the letters of credit.

As of December 31, 2025 and 2024, the undiscounted claims liability recognized by the Captive has been actuarially determined to approximate $125,829 and $128,263, respectively. The Captive has investments held for general and professional liability coverage of approximately $209,978 and $199,002 at December 31, 2025 and 2024, respectively.

The Hospital has recorded the claims liability recognized by the Captive, net of amounts related to affiliated Atlantic Health entities, in the amount of $116,680 and $118,516 in accrued employee benefits and other long-term liabilities and a corresponding long-term other asset for the amount recoverable from the Captive (Note 6) as of December 31, 2025 and 2024, respectively.

The Hospital is subject to claims in the ordinary course of its business. Management and its legal counsel do not believe these claims will be in excess of the recorded liability.

(in thousands)

12. Related Party Transactions

Due from affiliates, net, as of December 31, 2025 and 2024, consists of the following and are recorded in other current assets, long-term investments and other assets, and accrued employee benefits and other, net of current portion in the consolidated balance sheets:

	2025	2024
Other current assets		
Due from Atlantic Health	$ 42,194	$ 57,267
Due from Atlantic Ambulance	79,150	63,510
Due from AHSIC	62,824	42,749
Due from CentraState	3,140	15,573
Due from Accountable Care Organizations	704	2,149
Due from affiliated foundations	428	213
Due from Primary Care Partners	123	403
Due from Atlantic Health Partners	273	427
Due from Urgent Cares	4,007	2,428
	192,843	184,719
Less: Allowance for doubtful accounts	(27,458)	(22,902)
	165,385	161,817
Long-term investments and other assets (Note 6)		
CentraState related party loans	113,816	113,816
AHSIC related party loans	107,407	112,200
Due from affiliated foundations	53,830	52,601
	275,053	278,617
Accrued employee benefits and other, net of current portion		
Due to AHSIC	(1,246)	(1,573)
Due from related parties, net	$ 439,192	$ 438,861

The Hospital is reimbursed by the above related parties for operating costs paid by the Hospital on their behalf. These costs include but are not limited to payroll and employee benefits, office charges and supplies and other expenses of the related party as warranted. The due from affiliated foundations include amounts donated to the affiliated foundations for the benefit of the Hospital. The amounts are held by the affiliated foundations until the purpose and/or time restriction has been met.

In addition, during each of the years ended December 31, 2025 and 2024, the Hospital recorded equity transfers on the consolidated statement of operations. The equity transfers are to Atlantic Health and other affiliated entities controlled by Atlantic Health primarily to support the operations of and invest in those entities to further the overall continuum of care to patients.

(in thousands)

As of December 31, 2025 and December 31, 2024, the Hospital owes $1,246 and $1,573 to AHSIC for leasehold improvements, respectively. In addition, the Hospital, as lessee, contracts for operating leases with AHSIC. The description of leases and related lease expenses are as follows for the years ended December 31, 2025 and 2024:

	2025	2024
Medical office buildings, apartments, houses and office space for hospital employees	$ 9,875	$ 9,638

As of December 31, 2025, the future minimum commitments under these leases are as follows:

2026	$ 10,004
2027	9,629
2028	9,010
2029	8,499
2030	8,487
Thereafter	50,863
Total minimum lease commitments	96,492
Less: Imputed interest	(18,326)
Present value of lease liabilities	78,166
Less: Current portion of lease liabilities	(6,957)
Long-term lease liabilities	$ 71,209

Minimum lease commitments with related parties after 2030 include $18,663 associated with renewal options that are reasonably certain to be exercised.

13. Commitments and Contingencies

At December 31, 2025 and 2024, information technology contracts of $21,113 and $11,330, respectively, and construction contracts and purchases of equipment of $35,382 and $56,604, respectively, exist for on-going capital projects at the various Hospital divisions.

The Hospital is subject to complaints, subpoenas, claims and litigation which have risen in the normal course of business. In addition, the Hospital is subject to reviews and investigation by various federal and state government agencies to assure compliance with applicable laws, some of which are subject to different interpretations. While the outcome of such matters cannot be determined based upon information available at this time, management, based on advice from legal counsel, believes that any loss which may arise from these actions will not have a material adverse effect on the financial position or results of operations of the Hospital.

(in thousands)

14. Functional Expenses

The consolidated financial statements report certain expense categories that are attributable to both health care services and general and administrative functions. Therefore, the natural expenses require allocation on a reasonable basis, that is consistently applied, across functional expense category. Salaries are allocated based on a percent-to-total of program salaries and general and administrative salaries to the applicable total expense categories. Costs not directly attributable to a function, including depreciation, amortization and interest, are allocated to a function based on the same allocation rates as salaries.

Total expenses related to providing both health care services and general and administrative functions for the years ended December 31, 2025 and 2024 are as follows:

	2025		
	Program Services	General and Administrative	Total
Salaries	$ 1,830,342	$ 345,239	$ 2,175,581
Supplies and other expenses	1,540,680	290,603	1,831,283
Employee benefits	391,950	73,929	465,879
Depreciation	162,780	30,704	193,484
Interest	42,118	7,944	50,062
Total expenses	3,967,870	748,419	4,716,289
Other components of net periodic benefit costs	5,503	-	5,503
	$ 3,973,373	$ 748,419	$ 4,721,792

	2024		
	Program Services	General and Administrative	Total
Salaries	$ 1,691,508	$ 329,702	$ 2,021,210
Supplies and other expenses	1,337,837	260,766	1,598,603
Employee benefits	343,628	66,979	410,607
Depreciation	153,306	29,882	183,188
Interest	46,691	9,101	55,792
Total expenses	3,572,970	696,430	4,269,400
Other components of net periodic benefit costs	5,843	-	5,843
	$ 3,578,813	$ 696,430	$ 4,275,243

(in thousands)

15. Net Assets With Donor Restrictions

Net assets with donor restrictions are as follows:

	December 31, 2025	December 31, 2024
Research	$ 8,879	$ 9,751
Construction projects	50,340	80,347
Purchase of plant and equipment	5,100	9,565
Scholarships and education	5,375	5,105
Program services	103,575	63,922
Net assets with donor restrictions for specified purposes	173,269	168,690
Net assets with donor restrictions for permanent endowment	57,260	55,238
	$ 230,529	$ 223,928

The original gift amounts of permanent endowment investments funds are $47,570 and $45,119 as of December 31, 2025 and 2024, respectively.

During 2025 and 2024, net assets were released from donor restrictions by incurring expenses satisfying the restricted purpose of purchasing capital equipment in the amounts of $26,818 and $21,006, respectively, and other noncapital purposes in the amounts of $16,713 and $15,827, respectively.

16. Liquidity and Availability of Resources

Financial assets available for general expenditures within one year of the balance sheet date consist of the following:

	2025	2024
Financial assets		
Cash and cash equivalents	$ 394,370	$ 244,580
Patient accounts receivable, net	469,763	465,950
Other current assets	164,620	130,406
	1,028,753	840,936
Liquidity resources		
Available line of credit	200,000	200,000
	$ 1,228,753	$ 1,040,936

(in thousands)

As part of the liquidity management strategy, the Hospital structures its financial assets to be available as its general expenditures, liabilities and other obligations come due. As part of the Hospital's liquidity management plan, cash in excess of daily requirements are invested in money market funds and mutual funds.

The Hospital has current assets limited to use for debt service and thus are not reflected above. Additionally, the Hospital has board designated assets, more fully described in Note 6, which are not available for general expenditure within the next year and are also not reflected in the amounts above. However, board designated amounts could be made available, if necessary, with board approval.

The Hospital also maintains letters of credit as discussed in Note 8.

17. Subsequent Events

Subsequent events, including disclosures related to the revolving credit agreement as noted in Note 8, have been evaluated through April 14, 2026, which is the date the consolidated financial statements were issued.

Consolidating Supplemental Information

AHS Hospital Corp.
Consolidating Statement of Operations
Year Ended December 31, 2025

(in thousands)

	AHMMC	AHOMC	AHNMC	AHCMC	AHHMC	AVN	Total AHS Hospital Corp.
Revenues, gains and other support							
Net patient service revenue	$ 2,599,245	$ 1,288,750	$ 255,030	$ 371,610	$ 166,300	$ 71,743	$ 4,752,678
Other revenue	65,971	8,622	1,773	2,563	1,095	2,649	82,673
Net assets released from restrictions	11,922	3,734	110	834	113	-	16,713
Total revenues, gains and other support	2,677,138	1,301,106	256,913	375,007	167,508	74,392	4,852,064
Expenses							
Salaries	1,152,381	578,019	128,836	186,397	78,848	51,100	2,175,581
Supplies and other expenses	1,042,062	498,904	86,886	127,619	67,673	8,139	1,831,283
Employee benefits	238,159	122,778	31,324	40,784	18,763	14,071	465,879
Depreciation and amortization	106,392	48,853	13,514	15,742	7,991	992	193,484
Interest	26,953	12,286	2,344	5,261	3,218	-	50,062
Total operating expenses	2,565,947	1,260,840	262,904	375,803	176,493	74,302	4,716,289
Operating income (loss)	111,191	40,266	(5,991)	(796)	(8,985)	90	135,775
Change in net unrealized gains	56,658	27,097	5,932	8,016	3,807	1,831	103,341
Investment income, net	122,659	58,663	12,842	17,353	8,242	3,963	223,722
Nonoperating losses, net	(3,277)	(1,567)	(343)	(464)	(220)	(106)	(5,977)
Excess of revenues over expenses	$ 287,231	$ 124,459	$ 12,440	$ 24,109	$ 2,844	$ 5,778	$ 456,861

The accompanying note is an integral part of the consolidating supplemental information.

AHS Hospital Corp.
Consolidating Statement of Operations
Year Ended December 31, 2024

(in thousands)

	AHMMC	AHOMC	AHNMC	AHCMC	AHHMC	AVN	Total AHS Hospital Corp.
Revenues, gains and other support							
Net patient service revenue	$ 2,370,650	$ 1,128,738	$ 228,469	$ 355,656	$ 158,313	$ 66,555	$ 4,308,381
Other revenue	43,866	1,849	252	482	79	2,095	48,623
Net assets released from restrictions	10,565	4,524	47	605	86	-	15,827
Total revenues, gains and other support	2,425,081	1,135,111	228,768	356,743	158,478	68,650	4,372,831
Expenses							
Salaries	1,076,543	520,721	122,856	176,684	74,485	49,921	2,021,210
Supplies and other expenses	913,348	417,405	78,957	118,554	61,424	8,915	1,598,603
Employee benefits	214,516	104,935	27,328	36,203	15,324	12,301	410,607
Depreciation and amortization	102,846	44,485	12,814	14,748	7,306	989	183,188
Interest	30,311	13,849	2,646	5,623	3,363	-	55,792
Total operating expenses	2,337,564	1,101,395	244,601	351,812	161,902	72,126	4,269,400
Operating income (loss)	87,517	33,716	(15,833)	4,931	(3,424)	(3,476)	103,431
Change in net unrealized gains	37,954	17,914	3,885	5,670	2,656	1,246	69,325
Investment income, net	82,342	38,865	8,429	12,300	5,762	2,704	150,402
Nonoperating losses, net	(3,120)	(1,472)	(319)	(466)	(218)	(102)	(5,697)
Excess (deficiency) of revenues over expenses	$ 204,693	$ 89,023	$ (3,838)	$ 22,435	$ 4,776	$ 372	$ 317,461

The accompanying note is an integral part of the consolidating supplemental information.

AHS Hospital Corp.
Note to Consolidating Supplemental Information
Years Ended December 31, 2025 and 2024

1. Basis of Presentation – Consolidating Supplemental Information

The accompanying consolidating supplemental schedules ("Supplemental Information") for the years ended December 31, 2025 and 2024 presented on pages 42-43 are prepared to satisfy reporting requirements for acute care hospitals operating in the State of New Jersey under regulation N.J.A.C. 8.96-1.1 et seq. and are derived from the underlying accounting records used to prepare the consolidated financial statements of the Hospital. Each of the individual columns of the Supplemental Information includes the operations of the five individual acute care hospital facilities within the Hospital which operate as divisions and not as separate corporations (the "Divisions") as further disclosed within Note 1 to the Hospital's consolidated financial statements. In addition to the five hospital Divisions, is AVN, as also disclosed in Note 1 of these consolidated financial statements.

Included within the Hospital's AHMMC Division column in the Supplemental Information is its wholly owned subsidiary and not-for-profit fundraising organization, MMCF (as disclosed in Note 1 of these consolidated financial statements). Accordingly, for operational purposes, management presents the operations of MMCF as part of the AHMMC Division.

Within each Division presented on the Supplemental Information are allocations of certain operating expenses and nonoperating revenues, relating to the Hospital's corporate activities, which allow for elimination amounts to be excluded from the consolidating schedules. The allocated expenses are generally based on the budgeted monthly salary and non-salary expenses. Employee benefits expense is allocated based on actual salary expenditures incurred on a monthly basis, interest expense is based on the actual projects at the respective Division, which were or are being funded through long-term debt facilities, and the changes in net unrealized gains, net and nonoperating gains, net are allocated based on the actual annual total operating revenue for each Division. Also allocated to each Division are the results of operations of AMG, the physician practice plan serving all of the Hospital Divisions. AMG's results of operations are allocated across the Divisions based primarily on the geographic location of the physician practices in relation to each Division.

Other than as described above, the Supplemental Information is prepared in accordance with accounting policies described in the accompanying notes to the consolidated financial statements. This Supplemental Information is not intended to be a presentation in accordance with accounting principles generally accepted in the United States of America as a result of the exclusion of other changes in net assets without donor restrictions which are reported below the performance indicator (excess (deficiency) of revenues over expenses). The Supplemental Information is presented for purposes of additional analysis of the results of operations and is not a required part of the consolidated financial statements.

Reclassifications
Certain previously reported amounts in the fiscal 2024 consolidating supplemental information have been reclassified in order to conform to fiscal year 2025 presentation.